ArticleMSMR2024
Post-acute sequelae of SARS-CoV-2 and kidney events in U.S. active component service members, March 1, 2020-September 30, 2022.
Article in MSMR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early evidence suggests that COVID-19 is linked to kidney-related events in older and hospitalized patients. This link has not, however, been explored among a younger, healthy population such as U.S. active component service members (ACSMs). This retrospective cohort study assessed the incidence of post-acute sequelae of SARS-CoV-2 (PASC) and kidney events between March 1, 2020 and September 30, 2022 in ACSMs with no prior history of kidney events. Among the study population (n=831,780), 1,975 (0.2%) kidney events were reported between 31 days and 6 months after COVID-19 test dates. The incidence rate of any kidney event was slightly higher among ACSMs who tested negative for COVID-19 (10.6 per 10,000 person-years) compared to ACSMs who tested positive (9.8 per 10,000 person-years). In adjusted models of incidence rate ratios (IRRs), older ACSMs evinced significantly higher rates of kidney events compared to younger ACSMs, and COVID-19 vaccination had a protective effect; this was true in both the COVID-19-positive and -negative groups, although the IRR magnitude was stronger in the COVID-19-positive group. PASC did not lead to an increased incidence of kidney events compared to the COVID-19-negative group among ACSMs, an overall young and healthy population. PASC-related kidney events were rare among a young, healthy population of ACSMs without prior history of kidney events. The incidence of kidney events among ACSMs was not higher in the COVID-positive group compared to the group that tested negative for COVID.
Indexed as
Identifiers
39736159PMC11741558What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.